BY LYDIE RASCHKA With a grant from the National Inclusion Project, the Marquis Studios Inclusion Program was launched in 2011. As the six year olds filled the sunny art studio, they chanted the teacher’s name, “Hiromi! Hiromi!” With her frizzy pigtails, crinkly-eyed smile, and blocky gray tunic, Hiromi Niizeki looked like a big first-grader herself. This was Ms. Niizeki’s second season teaching visual art in the Inclusion Program, a project designed by Marquis Studios. Marquis […]
BY JILL BARKER, DAVID HART AND TAMIE HOPP The Olmstead decision, which interprets the Americans with Disabilities Act, is so clear that persistent misinterpretation by federal agencies can only be described as purposeful. INTRODUCTION The 25th Anniversary of the American with Disabilities Act (ADA) on July 26, 2015 offers an opportunity to set the record straight about what the landmark Supreme Court decision, Olmstead v. L.C., 527 U.S. 581 (1999)1, actually says about the ADA’s […]
• LAU-7b is safe and well tolerated by adult Cystic Fibrosis (CF) patients • The pharmacokinetic profile fully achieved the protocol dose selection rationale • Study drug shows a convergence of multiple promising pharmacodynamic trends MONTREAL, June 15, 2015 /CNW Telbec/ – Laurent Pharmaceuticals Inc. announced today positive topline results from a Phase 1b clinical trial with LAU-7b in adult CF patients. LAU-7b is a novel oral formulation of fenretinide, a synthetic retinoid investigated for […]
